Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis

Ronan Talty; William Damsky; Brett King

doi:10.1016/j.jdcr.2021.08.012

Treatment of cutaneous sarcoidosis with tofacitinib: A case report and review of evidence for Janus kinase inhibition in sarcoidosis

JAAD Case Rep. 2021 Aug 20:16:62-64. doi: 10.1016/j.jdcr.2021.08.012. eCollection 2021 Oct.

Authors

Ronan Talty^{1

2}, William Damsky^{1

2}, Brett King¹

Affiliations

¹ Department of Dermatology, Yale University, New Haven, Connecticut.
² Department of Pathology, Yale School of Medicine, New Haven, Connecticut.

No abstract available

Keywords: JAK; JAK inhibitor; JAK, Janus kinase; JAK-STAT; Janus kinase; STAT, signal transducer and activator of transcription; sarcoidosis; tofacitinib.

Publication types

Case Reports

Grants and funding

UL1 TR001863/TR/NCATS NIH HHS/United States